Nasal Corticosteroids Market to Reach Over $11.4 Billion by 2034 Amid Rising Chronic Respiratory Disorders | Transparency Market Research, Inc.
December 02, 2024 06:32 ET
|
Transparency Market Research
Wilmington, Delaware, Transparency Market Research Inc.-, Dec. 02, 2024 (GLOBE NEWSWIRE) -- The global nasal corticosteroids market (marché des corticostéroïdes nasaux), valued at US$ 6.6 billion in...
Lyra Therapeutics Presents Clinical Data Demonstrating LYR-210’s Local Anti Inflammatory Effects for the Treatment of Chronic Rhinosinusitis
September 10, 2020 18:00 ET
|
Lyra Therapeutics
Two additional presentations highlight supporting data for LYR-210’s clinical program covering key clinical endpoints for CRS and Lyra’s XTreo™ drug release performance Findings presented at the...
Lyra Therapeutics to Present Data Supporting LYR-210 for the Treatment of Chronic Rhinosinusitis
September 03, 2020 16:05 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel...
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 05, 2020 16:05 ET
|
Lyra Therapeutics
- On track to report topline Phase 2 results for LYR-210 in chronic rhinosinusitis in 4Q 2020 - - Conference call and webcast today at 4:30 p.m. ET - WATERTOWN, Mass., Aug. 05, 2020 (GLOBE...
Lyra Therapeutics to Present at the BTIG Virtual Biotechnology Conference
August 04, 2020 16:05 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Announces Pamela Nelson as Senior Vice President of Regulatory Affairs
August 04, 2020 08:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics to Participate in Fireside Chat at the William Blair Biotech Focus Conference
July 30, 2020 16:05 ET
|
Lyra Therapeutics
WATERTOWN, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics to Report Second Quarter 2020 Financial Results and Provide Corporate Update
July 24, 2020 08:30 ET
|
Lyra Therapeutics
WATERTOWN, Mass., July 24, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Announces Robert Richard, Ph.D., as Senior Vice President of Research and Development
July 07, 2020 08:30 ET
|
Lyra Therapeutics
WATERTOWN, Mass., July 07, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...
Lyra Therapeutics Set to Join the Russell 2000® Index and Russell 3000® Index
June 25, 2020 08:00 ET
|
Lyra Therapeutics
WATERTOWN, Mass., June 25, 2020 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated...